Alnylam CEO John Maraganore: An Interview With "The Pink Sheet" DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
CEO of the RNAi pioneer talks about his company's "5x15" product development strategy and his hopes not to have to access the capital markets anytime soon.
You may also be interested in...
In part two of this interview, the Alnylam chief executive discusses the thought process behind the biotech’s cutback in staff this past January and its $87 million cash raise in February.
The RNAi-pioneering biotech is sitting in a different position than it was a year ago, about to take its lead candidate into pivotal studies and with a new partnership with Arrowhead and $87 million in proceeds from one of the largest follow-on public offerings in recent memory by a biotech firm.
CEO of the RNAI pioneer firm talks about life after the Roche collaboration and how its partnership with Takeda is different.